has been used for advanced or recurrent gastric carcinomas. However, the therapeutic effect of chemotherapy has been insufficient and unsatisfactory. Paclitaxel (Taxol; Bristol Myers Squibb, Princeton, NJ, USA), which was recently developed and approved for several kinds of human cancers, such as ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer, might be a promising agent. The response rate of paclitaxel for gastric cancer was reported to be 28% as a single agent [1] , and the response rate as second-or third-line chemotherapy was relatively high
has been used for advanced or recurrent gastric carcinomas. However, the therapeutic effect of chemotherapy has been insufficient and unsatisfactory. Paclitaxel (Taxol; Bristol Myers Squibb, Princeton, NJ, USA), which was recently developed and approved for several kinds of human cancers, such as ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer, might be a promising agent. The response rate of paclitaxel for gastric cancer was reported to be 28% as a single agent [1] , and the response rate as second-or third-line chemotherapy was relatively high (20% [2] ).
Paclitaxel is a microtubule-disrupting agent and is thought to act by binding to beta-tubulin, which is a subunit of tubulin [3] . Paclitaxel induces microtubulin polymerization and inhibits depolymerization [4] , which finally blocks the cell cycle in the metaphase [5, 6] .
The beta-tubulin gene is localized in chromosome region 6p21.3 and includes four exons [7] . The deduced protein has 444 amino acids. The binding site of paclitaxel in beta-tubulin has been detected in the Nterminal 31 amino acids [8] , which are encoded by exons 1 and 2 of the gene.
Schibler and Cabral [9] reported finding beta-tubulin gene mutations in paclitaxel-selected Chinese hamster ovary cells and in human small-cell lung cancer cells [10] which showed chemoresistance to paclitaxcel. Furthermore, Monzo et al. [11] reported that 16 (33%) of 49 NSCLCs showed genetic mutations in the beta-tubulin gene, and none of the patients with beta-tubulin mutations had an objective response to paclitaxel.
These reports suggest that gene mutations of betatubulin may induce a change in microtubule dynamics and prevent paclitaxel from binding to the beta-tubulin molecule, which would result in resistance to the agent.
The purpose of this study was to examine the mutation status of the beta-tubulin gene in gastric cancer and to predict the chemoresistance, in patients with gastric cancer, to paclitaxcel, a promising antitumor agent.
Introduction
Gastric carcinoma is one of the most lethal and frequent malignancies in Japan. Chemotherapy with a single anticancer agent or a combination of anticancer agents
Subjects, materials, and methods

Specimens and DNA extraction
Fifty pairs of gastric tumor tissues and corresponding normal gastric mucosae were obtained from operations performed at the Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University. The specimens were dissected and stored at Ϫ80°C until DNA extraction. Genomic DNAs were extracted from the frozen tissues by using Sepagene (TaKaRa and Sankou Junyaku, Tokyo Japan) according to the manufacturers' instructions. All specimens were collected after written informed consent was obtained from the patients.
Polymerase chain reaction (PCR)
The primer sets were designed to amplify the whole coding region of the beta-tubulin gene, including four exons ( Fig. 1 and Table 1 ). As exon 4 is 1059 base pairs long, its entire length was amplified first, then divided into four regions which were amplified using nested PCR. The PCR reaction mixture contained 100 ng of template DNA, 2 p-mol of each primer set, 0.5 U of Taq polymerase (AmpliTaq Gold; Roche Molecular Systems, NJ, USA), and 2.5 mM MgCl 2 . The PCR cycling conditions were as follows: an initial denaturing step at 95°C for 10 min, and 40 cycles at 95°C for 30 s, 50°C-58°C for 30 s, and 72°C for 30 s, followed by a final period of extension at 72°C for 5 min. For Each primer pair was designed in franking introns for amplification of each exon according to the beta-tubulin gene sequence (GenBank accession no. J00314) [15] . After the whole region of exon 4 was amplified, the four divided regions were amplified by the nested PCR primers shown PCR, polymerase chain reaction amplification of the whole region of exon 4, the extension time was extended for 2 min.
Single-strand conformation polymorphism (SSCP) analysis
SSCP analysis was performed using 5% nondenaturing polyacrylamide gels (acrylamide/N,N-bisacrylamide 99:1) containing 10% glycerol. After electrophoresis for 4.5 h at 850 V, the gels were stained with SYBR Green II (TaKaRa, Otsu, Japan) and scanned with a fluorescence image analyzer (FM Bio Multi-View; TaKaRa).
Sequence analysis
The bands shifting on SSCP were cut out and amplified by PCR. PCR products were purified, and the sequence was analyzed using a Direct Sequence Kit (Big Dye Terminator version 3 Cycle Sequencing Ready Reaction Kit; Perkin-Elmer, MA, USA).
Results and discussion
The clinicopathological characteristics of the 50 patients whose tissues were examined in this study are listed in Table 2 . None of the patients had had taxan-based che- motherapy. The SSCP analysis showed variant bands from exon 1 to exon 4 of the beta-tubulin gene (Fig. 2) . The sequence analysis showed that 20 patients (40%) had a nucleotide change in the intron at 85 base pairs downstream of exon 1. Similarly, 4 (8%) and 3 (6%) patients, respectively, had a nucleotide change in the intron at 32 base pairs downstream of exon 2 and in the intron at 16 base pairs downstream of exon 3. In exon 4, 9 of the 50 tumors (18%) had a sequence of CTA (Leu) and the remaining 41 showed CTG (Leu) at codon 217, and TGTAETGC (Cys) at codon 303 (Fig. 3, Table 3 ). Taxanes, binding to beta-tubulin molecules, inhibit depolymerization, and induce an unusual polymerization and increase in the diameter of microtubules. Consequently, cell division is blocked and the cell cycle stops. Taxanes have a binding domain at the N-terminal region of beta-tubulin, which is coded by exons 1 and 2 of the gene. Several guanosine triphosphate (GTP) binding sites of beta-tubulin have been located in the region encoded by exon 4 [12] . Therefore, it is speculated that if there are mutations in exon 1 or exon 2 of the beta-tubulin gene, paclitaxel cannot bind to beta-tubulin, and if the mutations exist in exon 4, GTP cannot promote microtubule assembly, and paclitaxelinduced abnormal polymerization may not occur [6, 13] . Thus, beta-tubulin gene mutation may be associated with the resistance to taxanes.
Recently, beta-tubulin gene mutations have been identified in 33% of 49 patients with non-small cell lung cancer (NSCLC) given paclitaxel-based chemotherapy. Furthermore, none of the patients with beta-tubulin mutations had objective responses to taxanes [11] . In this study, we showed that there were no mutations of the beta-tubulin gene in gastric cancer. The difference may be that beta-tubulin mutations were specific to NSCLC, which may have been associated with NSCLC progression. Our results showed that, in gastric cancer, examination of beta-tubulin gene mutation might not be a useful predictor of resistance to paclitaxel-based neoadjuvant chemotherapy.
Dumontet et al. [14] have reported that beta-tubulin has intronless pseudogenes, which may be amplified by PCR with primer sets designed within exons. Kelley et al. [15] demonstrated that, in NSCLC, the primers used by Monzo [11] amplified a highly homologenous pseudogene (AF252825), which was located at 8p12, and primer sets newly designed by themselves did not amplify the pseudogene. Hasegawa et al. [16] also showed that, using breast-cancer tissues, primer sets designed in the sequence of exon 4 picked up the pseudogene, and the primer sets designed for nested PCR, using the outer PCR product amplified by the intronic primer set, did not amplify the pseudogene. Therefore, most of the mutations reported previously may be attributed to sequence differences between the beta-tubulin gene and pseudogenes.
Other molecules should be examined to predict the chemosensitivity of taxanes for gastric cancer. For example, there may be a need to elucidate the mechanism of cell death after damage to microtubules. Other studies have shown that overexpression of bcl-2 or bcl-XL inhibits paclitaxel-induced apoptosis without affecting anti-microtubule function or cell-cycle blockage [17] . Raf/bcl-2 phosphorylation is thought to be a later step after damage to the microtubules [18] . Nishio et al. [19] suggested that inhibition of mitogen-activated protein (MAP) kinase and cdc2 kinase, caused by paclitaxel, enhanced the interaction between tubulin and microtubule-associated protein 2.
In conclusion, examination of beta-tubulin gene mutations in gastric cancers cannot give sufficient information for the prediction of chemoresistance to taxanes. Further studies are needed to identify predictive molecules.
